Harmony Biosciences Holdings (HRMY) Net Income towards Common Stockholders (2019 - 2026)

Harmony Biosciences Holdings' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $32.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 28.69% year-over-year to $32.5 million; the TTM figure through Mar 2026 stood at $160.2 million (down 12.04% YoY), while the FY2025 annual figure was $173.3 million, down 0.94% from the prior year.
• Net Income towards Common Stockholders came in at $32.5 million for Q1 2026 at Harmony Biosciences Holdings, down from $37.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $87.9 million in Q3 2022 to a low of -$37.4 million in Q4 2022.
• A 5-year average of $35.6 million and a median of $37.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 1014.17% in 2022 and fell as far as 264.81% in 2022.
• Harmony Biosciences Holdings' Net Income towards Common Stockholders stood at -$37.4 million in 2022, then surged by 171.08% to $26.6 million in 2023, then soared by 196.69% to $78.9 million in 2024, then plunged by 52.98% to $37.1 million in 2025, then retreated by 12.46% to $32.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $32.5 million, $37.1 million, and $50.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison